HER2 as a prognostic and predictive marker for breast cancer
HER2 as a prognostic and predictive marker for breast cancer
复制标题
DOI：
10.1023/a:1011159723172
复制
发表时间：
2001-01-01
影响因子：
50.5
通讯作者：
Stanton, P
中科院分区：
文献类型：
--
作者：
Cooke, T;Reeves, J;Stanton, P
近年来，研究人员研究了人表皮生长因子受体-2（HER 2），该受体在20%-30%的乳腺癌患者中过表达，其作为预后和预测因子的作用。尽管许多研究表明HER 2过表达可能与不良临床结局相关，但其他研究并不完全支持这一观察结果。研究之间的不一致可能部分是由于不同HER 2检测方法之间的差异。为了克服这个问题，放射免疫组化方法被开发来定量测量乳腺肿瘤样品中的HER 2过表达水平。该方法的应用表明，所有乳腺肿瘤样本中有85%的HER 2表达水平高于正常水平。其中，23%的人表达HER 2，其水平是正常人的45至480倍，这与临床结果较差有关。HER 2状态作为治疗反应的预测因子的研究也产生了许多相互矛盾的结果。总体而言，HER 2过表达可能与对激素治疗的耐药性、对蒽环类化疗的敏感性和对CMF的耐药性相关。随着靶向抗HER 2治疗的发展，评估HER 2状态对于将患者分层至最合适的治疗方案将非常重要。
In recent years investigators have looked at the human epidermal growth factor receptor-2 (HER2), which is overexpressed in 20%-30% of breast cancer patients, with regard to its role as a prognostic and predictive factor. Although many studies have suggested that HER2 overexpression may be associated with a poor clinical outcome, other studies have not fully supported this observation. The inconsistencies between studies may be due in part to discrepancies between different HER2 testing methods. To overcome this problem, a radioimmunohistochemical method was developed to quantitatively measure HER2 overexpression levels in breast tumor samples. The application of this method demonstrated that 85% of all breast tumor samples expressed HER2 at levels greater than normal. Of these, 23% expressed HER2 at levels between 45 and 480 times greater than normal, and this was associated with poor clinical outcome. The investigation of HER2 status as a predictor of response to therapy has also yielded many conflicting results. Overall, it appears that HER2 overexpression may correlate with resistance to hormonal therapy, sensitivity to anthracycline-based chemotherapy and resistance to CMF. With the development of targeted anti-HER2 therapies, assessment of HER2 status will be important in stratifying patients to the most appropriate treatment regimens.